Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression?

Abstract

Background Conflicting data regarding the efficacy of antidepressants of different mechanism of action on unexplained painful physical symptoms (UPPS) in depression have been published so far.

Objective The aim of this study was to compare the impact of escitalopram (ESC), nortriptyline (NOR), and venlafaxine (VEN) on UPPS in patients with major depression.

Materials and methods Sixty patients, participants in the GENDEP study, with a diagnosis of depression according to the ICD-10 criteria were randomly assigned to treatment with ESC (10–30 mg, mean dose 15.2, standard deviation [SD]±9.2) or NOR (50–150 mg, mean dose 106.2, SD±8.2). Additionally, 30 patients who were treated with VEN (75–225 mg, mean dose 181.3, SD±8.8) were included. Before inclusion (day 0) and throughout the study (days 14, 28, 42, 56), the severity of pain was monitored using the visual analog scale.

Results The patients treated with ESC, NOR, and VEN did not differ in the intensity of pain at days 0, 14, 28, 42, and 56.

Conclusion Our results do not support the hypothesis suggesting the superiority of VEN over ESC and NOR in the management of UPPS in major depression.

Key words

unexplained painful physical symptoms - major depression - nortriptyline - escitalopram - venlafaxine

• References

• 1 Demyttenaere K, Bonnewyn A, Bruffaerts R. et al. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disord. 2006; 92: 185-193
• 2 Husain MM, Rush AJ, Trivedi MH. et al. Pain in depression: STAR*D study findings. J Psychosom Res. 2007; 63: 113-122
• 3 Demyttenaere K, Reed C, Quail D. et al. Presence and predictors of pain in depression: Results from the FINDER study. J Affect Disord. 2010; 125: 53-60
• 4 Agüera-Ortiz L, Failde I, Mico JA. et al. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. J Affect Disord. 2011; 130: 106-112
• 5 Bair MJ, Robinson RL, Eckert GJ. et al. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004; 66: 17-22
• 6 Kroenke K, Shen J, Oxman TE. et al. Impact of pain on the outcomes of depression treatment: Results from the RESPECT trial. Pain 2008; 134: 209-215
• 7 Karp JF, Scott J, Houck P. et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005; 66: 591-597
• 8 Fuller-Thomson E, Battiston M, Gadalla TM. et al. Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample. Soc Psychiatry Psychiatr Epidemiol 2014; 49: 903-910
• 9 Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med. 2004; 19: 813-818
• 10 Greenberg PE, Leong SA, Birnbaum HG. et al. The economic burden of depression with painful symptoms. J Clin Psychiatry 2003; 64 (Suppl. 07) 17-23
• 11 Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. J Clin Psychiatry. 2006; 67: 1232-1239
• 12 Finnerup NB, Attal N, Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015; 14: 162-173
• 13 Griebeler ML, Morey-Vargas OL, Brito JP. et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014; 161: 639-649
• 14 Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain. 2013; 29: 1021-1028
• 15 VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015; 40: 1-6
• 16 Chappell AS, Bradley LA, Wiltse C. et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008; 1: 91-102
• 17 Häuser W, Wolfe F, Tölle T. et al. The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis. CNS Drugs 2012; 26: 297-307
• 18 Stahl S. The psychopharmacology of painful symptoms in depression. J. Clin Psychiatry 2002; 63: 382-383
• 19 Fava M, Mallinckrodt CH, Detke MJ. et al. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry 2004; 65: 521-530
• 20 Brannan SK, Mallinckrodt CH, Brown EB. et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005; 39: 43-53
• 21 Raskin J, Wiltse CG, Siegal A. et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164: 900-909
• 22 Thaler KJ, Morgan LC, Van Noord M. et al. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety. 2012; 29: 495-505
• 23 Krebs EE, Gaynes BN, Gartlehner G. et al. Treating the physical symptoms of depression with second-generation antidepressants: A systematic review and metaanalysis. Psychosomatics 2008; 49: 191-198
• 24 Jaracz J, Gattner K, Moczko J. et al. Comparison of the effects of ESC and NOR on painful symptoms in patients with major depression. Gen Hosp Psychiatry 2015; 37: 36-39
• 25 Uher R, Huezo-Diaz P, Perroud N. et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009; 9: 225-233
• 26 Uher R, Perroud N, Ng MY. et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010; 167: 555-564
• 27 Hamilton M. Development of a rating scale for primary depressive illness. British J Clin Psychol 1967; 6: 278-296
• 28 Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain. 2003; 4: 2-21
• 29 Li L, Liu X, Herr K. Postoperative pain intensity assessment: A comparison of four scales in Chinese adults. Pain Medicine. 2007; 8: 223-234
• 30 Breivik EK, Björnsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000; 16: 22-28
• 31 Cocksedge K, Shankar R, Simon C. Depression and pain: the need for a new screening tool. Prog Neurol Psychiatry 2016; 20: 26-32
• 32 Jaracz J, Gattner K, Jaracz K. et al. Unexplained painful physical symptoms in patients with major depressive disorder: Prevalence, pathophysiology and management. CNS Drugs 2016; 30: 293-304
• 33 Martinez JM, Katon W, Greist JH. et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2012; 27: 17-26
• 34 de Silva VA, Hanwella R. Efficacy and tolerability of VEN versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. Int Clin Psychopharmacol 2012; 27: 8-16
• 35 Battiston M, Gadalla TM, Brennenstuhl S. Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample. Soc Psychiatry Psychiatr Epidemiol 2014; 49: 903-910
• 36 Hegerl U, Mergl R, Quail D. et al. Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine?. Pharmacopsychiatry 2012; 45: 114-118
• 37 Marangell LB, Clauw DJ, Choy E. et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and MDD: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011; 152: 31-37
• 38 Debonnel G, Saint-André E, Hébert C. et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007; 10: 51-61